Financial Performance - In the first half of the year, the revenue from CDMO services reached over 10 million, primarily from domestic clients [2] - The company maintains a cautious approach to capacity expansion, planning based on product pipeline and client demand [2] - The revenue from domestic clients in the CDMO sector is growing faster than that from overseas clients, with domestic revenue growth attributed to enhanced brand influence and successful project experiences [4] Client Engagement and Market Strategy - The company has a high project retention rate, indicating client satisfaction with services and technical capabilities [4] - The proportion of foreign clients in CDMO revenue is between 60% to 70%, while domestic clients account for 30% to 40% [3] - The company aims to deepen foreign clients' understanding of its CMC capabilities through market expansion efforts [4] Organizational Adjustments - The company restructured its R&D and CDMO divisions to better align with current business development needs, enhancing internal collaboration [4] - The financial reporting structure was adjusted to reflect the evolution of the business model, moving from weight-based classifications to molecular blocks and CDMO categories [4] New Drug Development - The New Drug Discovery Division has established high-quality compound libraries and has completed multiple target screenings, showing promising activity and drug-like properties [5] - Recent collaboration with Aidi Pharmaceutical on a 3CL protease inhibitor indicates ongoing advancements in drug discovery efforts [5]

Group 1: Financial Performance - The company achieved a 31% revenue growth in the first three quarters, with approximately 40% growth excluding large orders [4] - The molecular building block division experienced a growth rate of 44%, while the CDMO division grew by 28% [4] - The overall gross margin remains stable, with CDMO gross margin between 40%-45% and molecular building block gross margin between 55%-60% [4] Group 2: Market Expansion - The company has added 6,000 new molecular building block compounds to its inventory to meet overseas market demand [4] - In the domestic market, the company has gained recognition for its integrated CMC capabilities, engaging with 100 innovative drug companies and industry experts [2] - The management team has participated in multiple industry conferences in Europe and the US to enhance brand influence and attract new clients [2] Group 3: Operational Insights - The utilization rate of the existing workshop remains stable, with the new 502 workshop expected to reach normal production status by the end of the year [4] - The company is planning to launch the 503 workshop in the first half of 2023, with future workshops being designed as fully automated [4] - The increase in accounts receivable turnover days is attributed to the longer development cycle of API projects and some domestic clients experiencing slower payment due to funding issues [5] Group 4: Strategic Outlook - The company does not foresee significant impacts from international geopolitical factors on its business, as the demand for CDMO services remains strong [6] - The global CDMO market is highly fragmented, and the domestic CDMO sector is expected to grow at a rate higher than the global average [6] - The company has made optimizations in order acquisition and production delivery to reduce uncertainties in operations [6] Group 5: Emerging Business Areas - The company has formed a dedicated team to advance emerging business areas such as ADC, oligonucleotides, and PROTAC, with significant progress reported [6] - The company has completed research on all E3 ligases available in the market and is advancing linker design work [6]

Financial Performance - Revenue for Q3 2022 reached ¥450,058,731.03, an increase of 59.83% compared to the same period last year[5] - Net profit attributable to shareholders was ¥96,523,773.69, up 57.87% year-on-year[5] - Net profit excluding non-recurring items was ¥91,757,829.72, reflecting a 64.72% increase compared to the previous year[5] - Operating income increased by 107.42% to ¥19,198,057.75 compared to ¥9,255,542.90 in the same period last year[11] - Total operating revenue for the current period reached ¥1,184,702,109.49, a significant increase from ¥902,929,920.72 in the previous period, representing a growth of approximately 31.2%[32] - Net profit for the current period was ¥261,286,132.90, compared to ¥451,168,056.54 in the previous period, reflecting a decrease of approximately 42.2%[34] - Earnings per share for the current period were reported at 1.2570, compared to 2.2399 in the previous period, indicating a decline of approximately 43.8%[34] Assets and Liabilities - Total assets as of September 30, 2022, amounted to ¥4,955,539,732.77, a 41.31% increase from the end of the previous year[5] - Current liabilities totaled approximately 1.28 billion yuan, compared to 788.88 million yuan in the previous year[28] - Long-term liabilities amounted to approximately 1.12 billion yuan, significantly higher than 90.33 million yuan in the previous year[28] - The company reported a total equity of approximately 2.55 billion yuan as of September 30, 2022[28] - The company’s total liabilities and equity increased to ¥4,955,539,732.77 from ¥3,506,922,491.19, reflecting a growth of about 41.3%[31] Cash Flow - Cash flow from operating activities for the year-to-date was ¥186,433,654.21, down 33.53% compared to the previous year[5] - Cash paid for purchasing goods and services increased by 38.58% to ¥596,044,900.65, primarily due to higher material procurement expenses[11] - Cash paid to employees surged by 79.20% to ¥352,418,090.14, reflecting an increase in workforce and salary expenses[11] - Cash received from borrowings rose significantly by 339.83% to ¥792,895,362.26, indicating increased bank loan amounts[11] - Cash paid for debt repayment increased by 240.48% to ¥409,679,206.00, reflecting higher repayments of due bank loans[11] - The company reported a net increase in cash and cash equivalents of $7,819,198.21, contrasting with a decrease of $374,555,376.31 in the prior period[41] Investment and Financing - Cash invested increased by 40.86% to ¥3,314,532,000.00, mainly due to higher purchases of financial products[11] - The company received cash from convertible bond fundraising amounting to ¥1,145,283,018.87, marking a new financing strategy[11] - Cash inflow from financing activities reached $1,938,178,381.13, a substantial rise from $180,273,159.65 in the previous period[41] - Net cash flow from financing activities improved to $1,004,307,342.88 from $40,005,468.30, reflecting a positive shift in financing operations[41] Research and Development - Research and development expenses rose by 48.79% to ¥121,203,263.82, indicating increased investment in innovation[10] - Research and development expenses increased to ¥121,203,263.82 from ¥81,457,397.06, marking a rise of approximately 48.8%[32] Shareholder Information - The total number of common shareholders at the end of the reporting period was 23,470, with the largest shareholder holding 20.69%[13] Revenue Breakdown - Revenue from the sub-block business reached 269 million yuan, a year-on-year increase of 44.19%[21] - CDMO revenue amounted to 909 million yuan, reflecting a year-on-year growth of 28.09%[21] - Domestic revenue was 372 million yuan, up 43.06% compared to the same period last year[21] - International revenue reached 812 million yuan, showing a year-on-year increase of 26.41%[21] - Overall gross margin for the first three quarters was 47.30%, slightly down from the previous year[21]

Financial Performance - PharmaBlock reported a revenue of RMB 300 million for the first half of 2022, representing a year-on-year increase of 25%[21] - The company's revenue for the first half of 2022 was ¥734,643,378.46, representing an increase of 18.23% compared to ¥621,349,416.99 in the same period last year[33] - Future guidance estimates a revenue growth of 20% for the second half of 2022, targeting RMB 360 million[21] - The company achieved a revenue of 735 million yuan, representing an 18.23% year-on-year growth; excluding the impact of a major client's project delivery cycle, revenue growth was 29.00%[64] - The company's operating revenue for the reporting period was ¥734,643,378.46, representing an increase of 18.23% compared to the same period last year[98] - The gross profit margin was 47.74%, slightly down from 49.64% in the previous year[65] - The gross profit margin for the CDMO segment was 43.17%, with a year-on-year decrease of 2.13%[101] Profitability and Expenses - Net profit attributable to shareholders decreased by 59.84% to ¥153,095,324.58 from ¥381,238,213.47 year-on-year[33] - Basic and diluted earnings per share fell by 60.10% to ¥0.77 from ¥1.93 in the same period last year[33] - The net cash flow from operating activities dropped significantly by 78.70%, amounting to ¥40,546,816.33 compared to ¥190,401,654.04 in the previous year[33] - R&D expenses amounted to 71.82 million yuan, an increase of 41.36% year-on-year, with an R&D expense ratio of 9.78%[65] - The company's human resources expenditure increased to 235.29 million yuan, a rise of 82.16% year-on-year, reflecting significant growth in personnel scale and compensation[65] Market Expansion and Client Base - User data indicates a 30% increase in the number of active clients compared to the same period last year, reaching 1,200 clients[21] - The company has expanded its market presence in Europe, achieving a 40% growth in sales in that region[21] - The company is actively expanding its customer base, with 26% of API and formulation CMC projects coming from long-term partnerships, and 40% of clients entering through CMC projects[69] - The number of kilogram-level terminal customers increased to 166, a year-on-year growth of 58%, with sales exceeding 5 million for 35 customers, up 30% year-on-year[70] Research and Development - The company plans to invest 15% of its revenue into R&D for new drug development and technology advancements[21] - PharmaBlock is focusing on the development of small molecule drugs, with 5 new compounds entering clinical trials by the end of 2022[21] - The company has established a diverse library of drug molecular building blocks, enabling rapid identification of candidate compounds for drug discovery[46] - The company has developed a high-standard one-stop CDMO service platform, providing comprehensive services for intermediates, APIs, and drug formulations[46] - The company has developed a library of 160,000 unique small molecule drug building blocks, significantly accelerating drug development for clients[50] - The company has implemented advanced continuous flow chemistry and micro-packed bed technologies, achieving industrial-scale production and reducing development cycles[53] Risk Management - The company has identified key risks including regulatory changes and supply chain disruptions, with strategies in place to mitigate these risks[21] - The company faced risks related to declining demand in the drug research and development market, which could negatively impact revenue growth if the global pharmaceutical market slows down[138] - The company has a high proportion of revenue from overseas sales, with contracts typically denominated in foreign currencies, exposing it to exchange rate fluctuations[141] Environmental Compliance - The company emphasizes environmental protection and safety in production, having not experienced major accidents, but acknowledges increasing pressure as business scales up[138] - The company has established a quality management system to ensure product quality, which is critical for its development[138] - The company has no reported instances of exceeding pollution discharge limits for wastewater, with total discharge amounts well within regulatory standards[161] - All companies reported no significant environmental pollution incidents during the reporting period[186] Employee Engagement and Governance - The company has implemented a stock incentive plan to enhance employee motivation and align their interests with shareholders[152] - Employee engagement initiatives included sports events and cultural activities, fostering a sense of belonging and enhancing team cohesion[195] - The company adheres to legal regulations and has improved its corporate governance structure to protect shareholder rights, ensuring timely and accurate information disclosure[192]

Financial Performance - PharmaBlock reported a cash dividend of 1.00 RMB per 10 shares to all shareholders, based on a total of 199,658,096 shares[5]. - The company's operating revenue for 2021 was CNY 1,201,629,070.94, representing a 17.55% increase from CNY 1,022,229,215.88 in 2020[30]. - The net profit attributable to shareholders in 2021 was CNY 486,559,403.95, a significant increase of 164.14% compared to CNY 184,207,681.24 in 2020[30]. - The net profit after deducting non-recurring gains and losses was CNY 232,996,748.92, up 34.24% from CNY 173,573,289.18 in 2020[30]. - The basic earnings per share for 2021 was CNY 2.46, a 148.48% increase from CNY 0.99 in 2020[30]. - The total assets at the end of 2021 were CNY 3,506,922,491.19, with net assets attributable to shareholders increasing by 44.60% to CNY 2,427,424,730.19[30]. - The company reported a net cash flow from operating activities of CNY 238,029,950.44, a decrease of 12.33% from CNY 271,505,518.45 in 2020[30]. - The company achieved a total revenue of 1.202 billion RMB in 2021, representing a year-on-year growth of 17.55%[63]. - The net profit attributable to shareholders reached 487 million RMB, marking a significant year-on-year growth of 164.14%[64]. - The gross profit margin for 2021 was 48.13%, showing a stable improvement compared to 2020[64]. - The company reported a total revenue of 32,104,530, with a net profit of 11,034,117, representing a decrease of 43,035,247 compared to the previous period[175]. - The company reported a significant increase in revenue, achieving a total of $500 million for the fiscal year, representing a 25% year-over-year growth[191]. Research and Development - The company specializes in the research, development, production, and sales of drug molecular building blocks, with a focus on innovative chemical products and services in the global drug development field[5]. - The company invested 114 million RMB in R&D expenses, which is a 25.40% increase year-on-year, with an R&D expense ratio of 9.49%[64]. - The number of R&D personnel increased to 243 in 2021, up 25.26% from 194 in 2020[106]. - R&D expenditure reached ¥114,023,944.60 in 2021, representing 9.49% of operating revenue, compared to 8.89% in 2020[106]. - The company has established a library of 150,000 unique drug molecular building blocks, significantly aiding clients in drug development[53]. - The company has developed advanced manufacturing models for biopharmaceutical products, focusing on green, safe, and intelligent production[50]. - The company has achieved breakthroughs in continuous flow chemistry, fixed-bed technology, and biocatalysis, enhancing its service offerings[50]. - The company constructed a virtual compound library containing over 10 billion compounds, significantly enhancing its drug discovery capabilities[83]. - The company aims to increase R&D investment, expanding service categories to include new drug types such as oligonucleotides, PROTAC, and ADC[151]. - Research and development expenses increased by 10%, totaling $80 million, reflecting the commitment to new technology advancements[191]. Market and Business Strategy - Future strategies may include market expansion and the development of new products and technologies[5]. - The company is focused on enhancing its capabilities in drug discovery and development through innovative chemical engineering technologies[103]. - The company has established a project pipeline with 1,430 projects in the preclinical to Phase II stages and 45 projects in Phase III to commercialization[65]. - The company has expanded its customer base, increasing the number of kilogram-level terminal customers to 144, a year-on-year growth of 15.5%, and the number of customers with sales exceeding $5 million to 58, a growth of 28%[68]. - The company is actively pursuing mergers and acquisitions to strengthen its market position and enhance operational capabilities[179]. - The company plans to expand its market presence and enhance product development, focusing on innovative technologies and new product launches[179]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of $100 million allocated for this purpose[191]. - The company plans to invest $20 million in digital marketing to boost brand awareness and customer engagement[191]. - The company is focused on improving its human resources planning and establishing a digital platform for talent management[153]. Risk Management - The company faces various risks including policy changes, intensified market competition, and potential declines in gross margin due to customer project progress[5]. - The report highlights potential impacts on sales growth due to the progress of clients' drug development projects[5]. - The company is committed to maintaining quality control and addressing environmental and safety production risks[5]. - The company has faced delays in project completion due to environmental control and weather factors[133]. Governance and Compliance - The company has established a comprehensive governance structure, ensuring effective decision-making and compliance with legal regulations[158]. - The company maintains complete independence from its controlling shareholders in terms of assets, personnel, finance, organization, and business operations[160]. - The company has established an independent financial department with specialized personnel, ensuring financial operations are separate from controlling shareholders[163]. - The company has a clear and independent asset ownership structure, with no legal disputes or potential disputes regarding its assets[163]. - The company has a well-defined corporate governance structure, including a shareholders' meeting, board of directors, and supervisory board, all operating independently[163]. Subsidiaries and Acquisitions - The company completed the acquisition of a 16.5% stake in Zhejiang Huishi, which became a subsidiary, resulting in a gain of CNY 222,274,540.92 from the revaluation of previously held shares[36]. - The company has initiated the establishment of new subsidiaries, including Shanghai Yaoshiyuan and Jiangxi Shangshi, which are yet to commence operations[149]. - The acquisition of Zhejiang Huishi is expected to strengthen the company's strategic development and resource integration[149]. - The subsidiary, American Yaoshi, reported total assets of CNY 260,737.144 million and a net profit of CNY 2,924.841 million[143]. - The company recorded a net loss of 7,602,827.93 for the subsidiary Yaojiankangke, indicating challenges in profitability[146]. Sustainability and Social Responsibility - The company is committed to achieving carbon neutrality goals while enhancing operational efficiency and reducing energy consumption[151]. - The management team emphasized a focus on sustainability initiatives, aiming to reduce carbon emissions by 30% over the next five years[191].

Financial Performance - The company's revenue for Q1 2022 was ¥335,643,580.55, representing a year-over-year increase of 17.44% compared to ¥285,807,823.32 in the same period last year[3] - Net profit attributable to shareholders was ¥70,839,845.23, a slight increase of 1.53% from ¥69,771,989.47 in the previous year[3] - Net profit for the current period was ¥74,367,424.72, representing a 6.3% increase from ¥69,771,813.76 in the previous period[32] - Total operating revenue for the current period reached ¥335,643,580.55, an increase of 17.4% compared to ¥285,807,823.32 in the previous period[29] - Total operating costs amounted to ¥254,700,510.42, up 15.5% from ¥220,439,922.16 in the prior period[29] - The total comprehensive income attributable to the parent company was 70,600,622.80, compared to 69,827,416.06 in the previous period, reflecting an increase[36] - Basic earnings per share increased to 0.36 from 0.35, while diluted earnings per share remained at 0.35[36] Cash Flow and Liquidity - The net cash flow from operating activities decreased significantly by 87.41%, amounting to ¥19,853,090.75 compared to ¥157,685,994.56 in the same period last year[3] - Cash received from sales decreased by 37.52% to ¥251,789,957.18, indicating a reduction in cash inflow from sales[10] - Cash flow from operating activities generated a net amount of 19,853,090.75, down from 157,685,994.56 in the previous period[37] - The cash and cash equivalents at the end of the period amounted to 691,525,233.54, down from 787,586,776.51 in the previous period[43] - The company received cash from borrowings amounting to 244,752,383.66, compared to 80,141,000.00 in the previous period[43] Assets and Liabilities - Total assets at the end of the reporting period reached ¥3,835,862,931.48, reflecting a growth of 9.38% from ¥3,506,922,491.19 at the end of the previous year[3] - Total liabilities rose to ¥1,129,809,341.60, up from ¥879,208,383.78, indicating a significant increase of 28.5%[28] - The company's equity attributable to shareholders reached ¥2,502,236,633.17, an increase from ¥2,427,424,730.19, marking a growth of 3.1%[28] - Total current assets reached CNY 2,001,628,652.05, an increase from CNY 1,804,007,753.77 at the beginning of the year, reflecting a growth of approximately 10.95%[22] - Non-current assets totaled CNY 1,301,000,000.00, with fixed assets valued at CNY 874,355,977.65, up from CNY 596,164,848.68[22] Shareholder Information - The company reported a total of 27,724 common shareholders at the end of the reporting period[15] - The largest shareholder, Yang Minmin, holds 20.68% of the shares, totaling 41,307,019 shares[15] - The company has a total of 36,578,332 restricted shares, with 595,875 shares released during the period[19] - The company plans to unlock 25% of the restricted shares annually based on the previous year's holdings[19] Operational Changes - The company's accounts receivable increased by 30.52%, reaching ¥262,707,551.34 due to expanded sales and revenue growth[7] - The company experienced a 117.41% increase in taxes and surcharges, amounting to ¥1,604,640.25, in line with the company's expanded scale[10] - The company invested ¥792,287,726.31 in new financial products, a decrease of 37.10% compared to the previous period, reflecting a reduction in cash scale[10] - Research and development expenses for the current period were ¥27,526,324.50, a decrease of 6.0% from ¥29,415,589.37 in the previous period[32] - The company is actively pursuing market expansion and new product development strategies[21] Investment Activities - Cash inflow from investment activities totaled 771,161,653.00, compared to 653,584,897.10 in the previous period[40] - Cash outflow from investment activities was 946,517,606.70, down from 1,318,987,083.86 in the previous period[40] - The company reported a financial expense of ¥122,095.61, compared to a financial income of ¥9,516,129.79 in the previous period[32] - The deferred income tax assets increased to ¥17,507,343.27 from ¥15,095,741.19, showing a growth of 16.0%[28]

Revenue and Profit - Revenue for Q3 2021 reached ¥281,580,503.73, an increase of 5.86% year-over-year, and year-to-date revenue was ¥902,929,920.72, up 24.47% compared to the same period last year[3] - Net profit attributable to shareholders for Q3 2021 was ¥61,139,845.82, reflecting an 11.16% increase year-over-year, while year-to-date net profit reached ¥442,378,059.29, a significant increase of 210.79%[3] - Basic earnings per share for Q3 2021 was ¥0.3096, up 6.06% year-over-year, and year-to-date basic earnings per share was ¥2.2399, an increase of 196.48%[3] - The net profit for the current period reached ¥451,168,056.54, a significant increase from ¥142,336,400.41 in the previous period, representing a growth of approximately 216%[31] - Operating profit rose to ¥463,997,310.40, compared to ¥159,791,605.86 in the previous period, indicating an increase of approximately 190%[31] - The total comprehensive income attributable to the parent company was ¥441,969,413.36, compared to ¥143,729,861.27 in the previous period, reflecting a growth of approximately 208%[34] Assets and Liabilities - Total assets as of September 30, 2021, amounted to ¥3,425,895,867.08, representing a 41.26% increase from the end of the previous year[3] - Total assets rose to ¥3,425,895,867.08, compared to ¥2,425,289,638.00, reflecting a growth of 41.3%[27] - Total liabilities increased to ¥884,670,164.68 from ¥530,568,842.44, a rise of 66.6%[27] - The company’s total liabilities increased significantly, with other payables rising by 144.25% to ¥170,581,634.56, mainly due to unpaid equity acquisition payments related to the Zhejiang Huishi acquisition[9] Cash Flow - The company’s cash flow from operating activities for the year-to-date was ¥280,486,246.32, reflecting a 63.37% increase compared to the same period last year[3] - Cash flow from operating activities netted ¥280,486,246.32, compared to ¥171,684,225.08 in the previous period, showing an increase of approximately 63%[35] - Cash received from investment activities increased by 334.82% to ¥2,081,124,500.00, driven by the purchase and redemption of financial products[9] - Investment activities generated a net cash flow of -¥693,221,828.81, compared to -¥17,822,647.70 in the previous period, indicating a significant increase in investment outflows[35] - Cash inflow from financing activities totaled $180,273,159.65, compared to $135,504,460.00 in the previous period, representing an increase of approximately 33%[41] - Net cash flow from financing activities was $40,005,468.30, down from $50,815,576.69, indicating a decrease of about 21%[41] - The ending balance of cash and cash equivalents was $866,160,060.83, compared to $340,432,092.04 in the prior period, showing a significant increase of approximately 154%[41] Investments and Acquisitions - The company reported a significant increase in goodwill to ¥356,185,571.87, a rise of 1041.50% due to the acquisition of Zhejiang Huishi[6] - The company’s long-term equity investments decreased by 94.48% to ¥8,599,762.10, primarily due to the acquisition of Zhejiang Huishi[6] - The company’s fixed assets increased by 310.83% to ¥567,408,211.24, attributed to the consolidation of Zhejiang Huishi[6] - Long-term deferred expenses increased by 208.99% to ¥7,253,341.03, primarily due to the acquisition of Zhejiang Huishi[9] - Other non-current assets rose by 728.67% to ¥55,580,283.44, mainly from increased prepayments for engineering and equipment[9] - Investment income surged by 6408.07% to ¥234,095,468.64, attributed to the revaluation of a 37.43% equity stake in Zhejiang Huishi acquired during the reporting period[9] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 16,291[13] - The largest shareholder, Yang Minmin, holds 20.68% of the shares, amounting to 41,307,019 shares[13] - The total number of restricted shares at the end of the period was 36,910,154, an increase from 28,302,372 at the beginning of the period[17] - The company plans to unlock 25% of restricted shares annually based on the previous year's holdings for executives[17] Expenses and Taxation - Total operating costs amounted to ¥671,997,967.05, up 18.4% from ¥568,120,590.43 in the previous period[28] - The company reported a 71.88% increase in taxes paid, totaling ¥39,321,299.94, due to higher income tax payments[9] - The company reported a tax expense of ¥21,884,710.21, down from ¥24,587,183.84, indicating a decrease of approximately 11%[31] Research and Development - Research and development expenses grew by 41.48% to ¥81,457,397.06, as the company continues to invest in technological innovation[9] - Research and development expenses increased to ¥81,457,397.06 from ¥57,574,920.12, marking a rise of about 42%[31] Other Financial Information - The company did not apply the new leasing standards for the first time in 2021, indicating no adjustments to prior financial statements[42] - The third quarter report was not audited, which may affect the reliability of the financial data presented[42]

Financial Performance - PharmaBlock reported a revenue of RMB 300 million for the first half of 2021, representing a year-over-year increase of 25%[2] - The company's operating revenue for the reporting period reached ¥621,349,416.99, representing a 35.24% increase compared to ¥459,451,937.03 in the same period last year[33] - The net profit attributable to shareholders was ¥381,238,213.47, a significant increase of 336.52% from ¥87,336,198.02 in the previous year[33] - The net cash flow from operating activities was ¥190,401,654.04, up 59.33% from ¥119,502,252.63 year-on-year[33] - The basic earnings per share rose to ¥1.93, reflecting a 319.57% increase compared to ¥0.46 in the same period last year[33] - The total assets at the end of the reporting period were ¥3,257,006,815.75, a 34.29% increase from ¥2,425,289,638.00 at the end of the previous year[33] - The company achieved a revenue of 621 million yuan, an increase of 35.24% compared to the same period last year[53] - The net profit attributable to shareholders, after deducting non-recurring gains and losses, reached 145 million yuan, up 77.16% year-on-year[53] - The company generated a net cash flow from operating activities of 190 million yuan, representing a year-on-year growth of 59.33%[53] Research and Development - PharmaBlock's R&D expenses increased by 30% compared to the previous year, reflecting its commitment to innovation and new technology development[2] - The company is investing in the development of new drug compounds, with a target of introducing 5 new products by the end of 2021[2] - The company is focused on innovation and new technology integration, developing a fragment library, DNA-encoded library, and virtual molecular library to enhance drug discovery efficiency[44] - The company has made significant breakthroughs in continuous flow chemistry, fixed-bed technology, and biocatalysis, aiming to provide more competitive products and services[44] - The company has designed over 130,000 compounds and conducted research on nearly 700 clinical candidates, adding over 500 new popular molecular building blocks[53] - The company has built a chiral compound library containing nearly 30,000 chiral compounds, with over 3,000 in stock[54] - The company applied for 8 invention patents during the reporting period, including 5 PCT applications, and received 12 patent authorizations[54] - The company has developed a unique artificial intelligence drug discovery platform based on multidimensional data and structural information, enhancing its drug candidate selection process[64] - The company has established a drug crystal engineering laboratory, completing 71 projects, including 33 kg-level projects[61] Market Expansion and Strategy - PharmaBlock's management highlighted a focus on expanding its market presence in North America and Europe, aiming for a 15% increase in market share by the end of 2022[2] - The company is exploring potential mergers and acquisitions to strengthen its portfolio and expand its capabilities in drug development[2] - The company maintains strong partnerships with major pharmaceutical firms, with over 70% of sales coming from international markets[48] - The company is actively pursuing partnerships and collaborations in the CDMO space to meet the increasing demand for high-quality production services[55] - The company has transitioned many projects from molecular building blocks to CDMO services, enhancing its service offerings and client relationships[65] Production Capacity and Quality Management - The company plans to enhance its production capacity by 20% in the next 12 months to meet growing demand[2] - The company is expanding its production capacity with a new GMP production workshop, which has a total capacity of 163m³ and can support production from clinical to commercial stages[58] - The company is constructing two new cleanroom production lines (502 and 503 workshops), expected to be completed in the first half of next year, enhancing automation and production efficiency[58] - The company is enhancing its quality management system, having passed 16 quality audits from well-known pharmaceutical companies[59] - The company has developed a comprehensive quality management system in compliance with international standards, enhancing its operational efficiency and product quality[77] Environmental Responsibility - The company emphasizes environmental protection and safety production, having invested in facilities to ensure compliance and prevent accidents[127] - The wastewater treatment processes across the companies ensure compliance with national discharge standards, reflecting a commitment to environmental responsibility[163] - The company has implemented measures to control noise pollution, including the use of low-noise equipment and sound insulation designs[168] - Environmental monitoring plans have been established and executed by the company, with third-party monitoring for wastewater and emissions in place[171] - There have been no administrative penalties related to environmental issues during the reporting period, reflecting the company's compliance with environmental regulations[172] Financial Management and Investments - The company has committed to investing raised funds according to the planned projects, with unutilized funds stored in a dedicated account[108] - The total investment amount during the reporting period was 316,744,190.51, a significant increase of 1,025.24% compared to the same period last year[92] - The company utilized 51.10 million yuan of raised funds during the reporting period, with a cumulative usage of 195.52 million yuan, achieving a usage progress of 107.01% as of June 30, 2021[99] - The company has no significant non-operating fund occupation by controlling shareholders or related parties, ensuring financial integrity[178] - The company has not issued any external guarantees that violate regulations, maintaining a sound financial position[179] Corporate Governance and Shareholder Engagement - The company held a performance briefing on March 26, 2021, attended by 367 investors via phone or online, discussing the 2020 annual performance and main business operations[132] - The first extraordinary general meeting of 2021 had an investor participation rate of 30.46% on January 7, 2021[135] - The company appointed a new general manager, Yang Minmin, and a new financial director, Wu Yifei, during the reporting period[138] - The company has implemented an employee stock ownership plan, with the first grant of restricted stock approved on September 10, 2019[140] - The company did not declare any cash dividends or bonus shares for the reporting period[6]

Financial Performance - The company's revenue for Q1 2021 reached ¥285,807,823.32, representing a 67.55% increase compared to ¥170,584,228.47 in the same period last year[8] - Net profit attributable to shareholders was ¥69,771,989.47, a significant increase of 147.31% from ¥28,212,630.51 in the previous year[8] - The net profit after deducting non-recurring gains and losses was ¥64,659,819.15, up 152.22% from ¥25,636,226.95 year-on-year[8] - Basic earnings per share were ¥0.45, a 136.84% increase from ¥0.19 in the previous year[8] - The company achieved operating revenue of CNY 285.81 million, a 67.55% increase compared to the same period last year[24] - The net profit attributable to shareholders reached CNY 69.77 million, reflecting a 147.31% year-on-year growth[29] - The company reported a net profit of ¥514,176,007.08 as of March 31, 2021, compared to ¥444,404,017.61 from the previous year, indicating an increase of about 15.7%[68] - Total operating revenue for the first quarter reached ¥285,807,823.32, a significant increase from ¥170,584,228.47 in the previous year, representing a growth of approximately 67.5%[75] - Net profit for the quarter was ¥69,771,813.76, compared to ¥28,212,434.60 in the same period last year, reflecting an increase of approximately 147.5%[81] Cash Flow and Investments - The net cash flow from operating activities was ¥157,685,994.56, showing a remarkable increase of 198.13% compared to ¥52,891,683.93 in the same quarter last year[8] - Cash and cash equivalents decreased by 36.48% to CNY 790.70 million due to increased investment in financial products[24] - The company reported a significant increase in investment income, with current period earnings of approximately ¥2.33 million compared to a loss of ¥1.16 million in the previous period[86] - The total cash outflow from investment activities is approximately ¥1.32 billion, compared to ¥231.96 million in the previous period, indicating a substantial increase in investment activities[97] - Cash flow from financing activities generated a net cash inflow of ¥47,760,000.00, down from ¥65,000,000.00 in the previous period[103] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,530,257,030.14, reflecting a 4.33% increase from ¥2,425,289,638.00 at the end of the previous year[8] - The total amount of short-term borrowings rose by 39.92% to CNY 168.51 million to supplement working capital[24] - Current liabilities totaled ¥496,861,454.22, slightly up from ¥475,938,909.59, indicating an increase of approximately 4.0%[65] - The total liabilities amounted to ¥555,300,191.20, compared to ¥530,568,842.44, reflecting an increase of about 4.7%[65] - The total non-current assets reached ¥612,348,167.93, up from ¥552,071,109.77, which is an increase of approximately 10.9%[62] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,563[12] - The largest shareholder, Yang Minmin, holds 20.68% of the shares, with a total of 31,774,630 shares[12] Research and Development - The company increased its R&D expenses by 73.18% to CNY 29.42 million, emphasizing its commitment to innovation[24] - Research and development expenses were ¥29,415,589.37, which is an increase from ¥16,985,603.04, showing a growth of about 73.4% year-over-year[78] - The company plans to focus on small molecule drugs over the next three years, enhancing R&D investment and integrating resources[29] Risk Management - The company plans to closely monitor regulatory changes in the pharmaceutical industry to mitigate risks associated with policy shifts[35] - The company is exposed to foreign exchange risks due to a high proportion of sales in foreign currencies, particularly USD[37] - The company has established a comprehensive quality management system to address potential quality control risks as it scales operations[39] Environmental and Social Responsibility - The company emphasizes environmental protection and safety in production, investing in facilities to manage waste and ensure compliance[36]

Financial Performance - The company's revenue for Q1 2021 was ¥285,807,823.32, representing a 67.55% increase compared to ¥170,584,228.47 in the same period last year[8] - Net profit attributable to shareholders was ¥69,771,989.47, a significant increase of 147.31% from ¥28,212,630.51 year-on-year[8] - The net profit after deducting non-recurring gains and losses was ¥64,659,819.15, up 152.22% from ¥25,636,226.95 in the previous year[8] - Basic and diluted earnings per share were both ¥0.45, reflecting a 136.84% increase compared to ¥0.19 in the previous year[8] - The company's gross profit margin for Q1 2021 was 47.47%, down from 51.59% in Q1 2020, indicating a potential risk of margin decline[37] - The total operating revenue for the first quarter was CNY 285,807,823.32, an increase of 67.5% compared to CNY 170,584,228.47 in the previous period[75] - Net profit for the quarter reached CNY 69,771,813.76, compared to CNY 28,212,434.60 in the same period last year, representing a growth of 147.5%[81] - Operating profit for the current period was ¥52,219,559.23, up from ¥26,464,532.00, reflecting a growth of 97.5%[89] - Net profit for the current period was ¥50,061,187.43, compared to ¥25,545,921.17 in the previous period, indicating a year-over-year increase of 96.2%[89] Cash Flow - The net cash flow from operating activities reached ¥157,685,994.56, marking a 198.13% increase from ¥52,891,683.93 in the same quarter last year[8] - Cash flow from operating activities totaled ¥157,685,994.56, up from ¥52,891,683.93, representing a growth of 197.5%[97] - The company reported a significant increase in cash inflow from sales of goods and services, totaling ¥402,970,635.81 compared to ¥202,111,978.73 in the previous period, an increase of 99.4%[93] - Total cash inflow from operating activities was ¥552,969,700.02, significantly higher than ¥215,244,906.41 in the prior period, indicating a growth of about 157.5%[100] - Cash outflow from operating activities totaled ¥489,207,976.79, compared to ¥154,432,217.22 in the previous period, representing an increase of approximately 216.5%[100] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,530,257,030.14, a 4.33% increase from ¥2,425,289,638.00 at the end of the previous year[8] - The total assets of the company increased to CNY 2,510,580,384.80 from CNY 2,490,060,532.47, showing a growth of 0.8%[75] - Current liabilities increased to approximately ¥496.9 million from ¥475.9 million, a rise of about 4.4%[65] - The total liabilities amounted to approximately ¥555.3 million, up from ¥530.6 million, representing an increase of about 4.7%[65] - Owner's equity rose to CNY 1,930,575,680.72, up from CNY 1,870,105,690.26, reflecting an increase of 3.2%[75] Research and Development - The company increased its R&D expenses by 73.18% to CNY 29.42 million, reflecting a commitment to innovation[24] - Research and development expenses were CNY 29,415,589.37, which is an increase of 73.5% from CNY 16,985,603.04 in the previous year[78] - The company plans to focus on small molecule drugs and enhance its R&D platform over the next three years[29] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,563[12] - The largest shareholder, Yang Minmin, held 20.68% of the shares, totaling 31,774,630 shares[12] Government Support and Subsidies - The company received government subsidies amounting to ¥3,829,399.99 during the reporting period[8] Market and Competition - The company is facing intensified market competition but aims to maintain its competitive edge through increased R&D investment and service capability enhancement[35] - The company emphasizes the importance of monitoring regulatory changes in the pharmaceutical industry to mitigate operational risks[35] Investment Activities - The company plans to issue 8,385,650 shares at a price of ¥111.50 per share, raising a total of ¥934,999,975.00, with a net amount of ¥928,090,177.20 after expenses[40] - The acquisition of a 16.5% stake in Zhejiang Huishi Pharmaceutical Co., Ltd. will increase the company's ownership to 53.93%, making it a subsidiary[41] Risk Management - Environmental protection and safety production measures are in place to mitigate risks associated with waste management and operational hazards[36] - The company is exposed to foreign exchange risks due to a high proportion of sales in foreign currencies, with strategies in place to hedge against these risks[37]